文献速递类风湿关节炎

基于超声预测类风湿关节炎停用生物制剂后复发的RA-BioStop研究

Ultrasound-based withdrawal of biologics in rheumatoid arthritis (RA-BioStop).
PubMed 文献 · RMD Open · 2026-08-07

RA-BioStop前瞻性试验纳入持续ACR/EULAR缓解的RA患者,停用bDMARD后52周内行9次访视(含14关节超声),检验基线Power Doppler评分≥1能否预测16周内复发。原计划110例,因招募不足38例(34.5%)终止。16周内复发在PD≥1组为9/30(30.0%),PD=0组为0/7(0%),p=0.160;主要终点未达到,数据为假设生成性。

要点

  • 研究因招募不足提前终止,主要终点未达到,结论仅为假设生成。
  • 基线PD评分≥1者16周内复发率30.0%,PD=0者0%,差异无统计学意义(p=0.160)。
  • 复发时PD评分较前次访视平均高3.2(±4.5)分(p=0.034)。

核心结论

  • 主要终点未达到,基线PD评分≥1未能显著预测停用bDMARD后16周内复发。
  • 数据应视为假设生成,用于启发超声评估RA缓解与预测复发的未来研究。

研究设计与样本

  • 前瞻性试验,纳入持续ACR/EULAR缓解并接受csDMARDs联合bDMARDs治疗的RA患者。
  • 停用bDMARD后52周内行9次访视,含临床检查与14关节超声(对临床数据设盲)。
  • 原计划纳入110例,因招募不足在38例(34.5%)时终止。

主要发现

  • 16周内复发在基线PD≥1组为9/30(30.0%),PD=0组为0/7(0%),p=0.160。
  • 第24周和第52周观察到类似趋势。
  • 复发时PD评分高于前次访视,平均差3.2(±4.5)分,p=0.034。
  • 16周内复发者基线PD评分有高于持续缓解者的趋势:5.2±5.8 vs 2.3±3.0,p=0.079。

关键数值与推荐

  • 主要假设:基线Power Doppler(PD)评分≥1预测停用bDMARD后16周内复发。
  • 复发定义:按简化疾病活动度评分从缓解变为中度/高度疾病活动。
  • 缓解标准:ACR/EULAR持续缓解。

临床怎么用

  • 本研究不足以支持以基线PD评分≥1作为停用bDMARD的决策依据。
  • 复发时PD评分升高提示超声或可作为监测工具,但需未来研究验证。

局限性

  • 研究因招募不足提前终止,样本量仅38例,统计效能不足。
  • 主要终点未达到,结果仅为假设生成,不能用于临床推荐。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To test whether ultrasonography of patients with rheumatoid arthritis (RA) in the American College of Rheumatology/the European Alliance of Associations for Rheumatology (ACR/EULAR) remission is useful for prediction of relapse after discontinuation of a biological disease-modifying antirheumatic drug (bDMARD). METHODS: Prospective trial including patients with RA in persistent ACR/EULAR remission treated with conventional synthetic DMARDs plus bDMARDs. After stopping the bDMARD, nine study visits including clinical examination and ultrasound of 14 joints (blinded to clinical data) were conducted within 52 weeks. The primary hypothesis was that a Power Doppler (PD) score≥1 predicted relapse occurring within week 16 after bDMARD cessation. Relapse was defined as a change from remission to moderate/high disease activity according to the Simplified Disease Activity Score. RESULTS: Inclusion of 110 patients was originally planned; however, the study was terminated after reaching 38 (34.5%) patients due to insufficient recruitment. Relapses till week 16 were numerically more common in patients with PD score≥1 at baseline than in those with PD=0 (9/30 (30.0%) vs 0/7 (0%), p=0.160). Similar observations were made for weeks 24 and 52. PD scores were higher at the time of relapse than at preceding visits (mean PD score difference: 3.2 (±4.5) points, p=0.034). There were trends towards a higher baseline PD score in patients who had a relapse until week 16 as compared with those who remained in remission (5.2±5.8 vs 2.3±3.0, p=0.079). CONCLUSION: The primary endpoint was not reached. The presented data should be interpreted as hypothesis-generating, serving to stimulate future research on the value of ultrasound in assessing remission and predicting relapse in RA. TRIAL REGISTRATION NUMBER: NCT01602302.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Dejaco C, Gessl I, Husic R, et al. Ultrasound-based withdrawal of biologics in rheumatoid arthritis (RA-BioStop). RMD Open. 2026. PMID: 42567558. doi:10.1136/rmdopen-2026-007003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。